Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session ...

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6% ... 75% had previously received AbbVie’s Venclexta (venetoclax), and 36% had tried three ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

One of the best ways to build wealth is with dividend stocks – especially if they’re attached to solid companies with a ...